CN1927878A - Clematis chinensis total saponin and treatment action thereof for rheumatoild disease - Google Patents
Clematis chinensis total saponin and treatment action thereof for rheumatoild disease Download PDFInfo
- Publication number
- CN1927878A CN1927878A CN 200510094339 CN200510094339A CN1927878A CN 1927878 A CN1927878 A CN 1927878A CN 200510094339 CN200510094339 CN 200510094339 CN 200510094339 A CN200510094339 A CN 200510094339A CN 1927878 A CN1927878 A CN 1927878A
- Authority
- CN
- China
- Prior art keywords
- root
- group
- arabinose
- saponin
- rhamnosyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
One kind of clematis total saponin is provided, which is effective components extracted from Chinese medicine material clematis root and contains clematis saponins CP1, CP2, CP2b, CP3b, CP3, CP4, CP5, CP6, CP7, CP8, CP9, CP10 and other triterpenoid saponin components. The pharmacological test on animal model of common inflammation and immune inflammation shows the obvious treating effect of the clematis total saponin and proves its important clinical treating value for rheumatic arthritis.
Description
Technical field
The present invention relates to the Radix Clematidis total glycosides that from the Chinese medicine Root of Sixpetal Clematis, extracts, and rheumatoid arthritis is had significant therapeutic action through the animal experiment proof.
Background technology
Root of Sixpetal Clematis is a wind-damp dispelling key medicine traditional on the tcm clinical practice, originates to be the dry root and rhizome of ranunculaceae plant Root of Sixpetal Clematis Clematis chinensisOsbeck, Clematis hexapetala Clematis hexapetala Pall. or northeast clematis Clematis manshurica Rupr..Warm in nature, flavor is hot, salty, and function is dispelled rheumatism, and is used for the treatment of the with a long history of " rheumatism ", the Zhou monarch's nest of the high sun Tang Dynasty is done " Root of Sixpetal Clematis biography " record: Root of Sixpetal Clematis removes many wind, the logical twelve regular channels, court dress is imitated dusk, dredges the cold purulence Su Shui of a surname's the five internal organs and becomes full, meagre profit is not rushed down the people, it is spry and light to obey these four limbs, and brothers are little warm, and get refrigerant.When elder generation, there was the sick hands and feet caused by paralysis of people in Shangzhou, do not carry out the ground many decades, and skilful doctor's skill of exhausting can not treated, by the road that the parent of institute puts, with the person for help, to meet new monk sieve and see it, can announcement is said: this disease one medicine be lived, but does not know that this soil has not? because the people go into the mountain and ask and adopt, fruit, be Root of Sixpetal Clematis also, make clothes, a few days energy stride.Thereafter Deng Siqi knows it, passes something then.Modern study shows that Root of Sixpetal Clematis has obvious anti-inflammatory and analgesic effect.But to its dispel rheumatism, the basic substance of relieving inflammation and relaxing pain do not appear in the newspapers as yet.Rheumatoid arthritis is a kind of autoimmune disorder of the chronic general based on arthropathy, and its course of disease is prolonged and repeated, the disability rate height.The chemical synthetic drug of Ying Yonging mainly contains glucocorticosteroid and NSAID (non-steroidal anti-inflammatory drug) clinically, but still can not definitely effect a radical cure this disease, and untoward reaction is more.Therefore countries in the world are devoted to traditional medicine is furtherd investigate, and therefrom extraction separation effective constituent and efficient part are sought good effect, the anti-inflammatory new drug of few side effects.
Summary of the invention
The objective of the invention is from traditional rheumatism Chinese medicine Root of Sixpetal Clematis, to extract the effective constituent of the experimental rheumatoid arthritis of treatment, so that further develop safe, effective, controlled Chinese medicine rheumatism new drug.That the medicine that the purified extract is used to prepare various formulations has is easy to detect, taking dose is little, easy administration, advantage that curative effect is high, the macroporous adsorbent resin method of preparation Radix Clematidis total glycosides has advantage simple to operate, that technical process is short, production cost is low among the present invention, has vast market prospect.
The present invention uses the macroporous adsorbent resin separating and purifying technology and extract the efficient part total saponins from Root of Sixpetal Clematis, is the triterpene saponin chemical ingredients, mainly contains following chemical ingredients, and its chemical structural formula is as follows:
R
1 R
2
Root of Sixpetal Clematis saponin(e CP
1OH 3-O-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
2H 3-O-α-L-rhamnosyl-(1-2)-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
2bH 3-O-β-D-wood sugar-(1-2)-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
3bOH 3-O-α-L-rhamnosyl-(1-2)-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
3H 3-O-β-D-wood sugar-(1-3)-α-L-rhamnosyl-(1-2)-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
4H 3-O-β-D-ribose-(1-3)-α-L-rhamnosyl-(1-2)-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
5OH 3-O-β-D-wood sugar-(1-3)-α-L-rhamnosyl-(1-2)-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
6OH 3-O-β-D-ribose-(1-3)-α-L-rhamnosyl-(1-2)-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
7H 3-O-β-D-glucose-(1-4)-β-D-ribose-(1-3)-α-L-rhamnosyl-(1-2)-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
8OH 3-O-β-D-glucose-(1-4)-β-D-ribose-(1-3)-α-L-rhamnosyl-(1-2)-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
9H 3-O-β-D-glucose-(1-4)-β-D-glucose-(1-4)-β-D-ribose-(1-3)-α-L-rhamnosyl-(1-2)
-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
10OH 3-O-β-D-glucose-(1-4)-β-D-glucose-(1-4)-β-D-ribose-(1-3)-α-L-rhamnosyl-(1-2)
-α-L-arabinose
Through animal experiment, find that above-mentioned Radix Clematidis total glycosides has remarkable therapeutic action to experimental rheumatoid arthritis, test method and result are as follows:
1 experiment material
1.1 laboratory animal:
Kunming mouse, male (being female in the hot-plate test), body weight 18～22g, available from management of laboratory animal center, Anhui Province Animal House, conformity certification number: No. the 01st, the real moving accurate word of Anhui doctor.The Wistar rat, male, body weight 180～220g, available from management of laboratory animal center, Anhui Province Animal House, conformity certification number: No. the 03rd, the real moving accurate word of Anhui doctor.20-25 ℃ of air-conditioning control room temperature, humidity 40-70% freely drinks water, and ingests.
1.2 medicine and reagent:
Radix Clematidis total glycosides (Total Saponins of Clematis), the time spent is mixed with the suspension of desired concn with purified water.Determine that the basic, normal, high dosage of mouse is respectively 37.5mg/kg, 75mg/kg, 150mg/kg.The basic, normal, high dosage of rat is respectively 25mg/kg, 50mg/kg, 100mg/kg.Tripterygium glycosides sheet: Zhejiang De'ende Pharmaceutical Co., Ltd., lot number 0311116.Determine that mouse dosage is 15mg/kg, rat dosage is 10mg/kg.Evans Blue, acetic acid, dimethylbenzene etc.: be analytical pure; Egg: commercially available.Freund's complete adjuvant, Shanghai Inst. of Biochemistry, Chinese Academy of Sciences, lot number 020605.
1.3 key instrument equipment:
The 8543E ultraviolet-visible spectrophotometer; U.S. Agilent company; BP211D 100,000/electronic balance; Germany Sartorius company; HH-S type constant water bath box: Henan Ying Yu gives magnificent instrument plant; Stopwatch: Shenzhen favour ripple science, industry and trade company; Rat foot volume determination device: this chamber self-control.Supercentrifuge, Shanghai Surgical Operation Equipment Factory; The 8543E ultraviolet-visible spectrophotometer, U.S. Agilent company.
2. method and result
2.1 causing the mouse vascular permeability, acetic acid increases test
50 of mouse are divided into normal control group, Radix Clematidis total glycosides 38,75,150mg/kg group and positive controls (tripterygium glycosides sheet), 10 every group at random.Every day gastric infusion once, for three days on end, 1h mouse tail vein injection 0.5% Evans Blue 5ml/kg after the last administration, the 5min pneumoretroperitoneum is injected 0.5% acetic acid 10ml/kg, mouse dislocation is put to death behind the 30min.Wash out intraperitoneal Evans Blue liquid repeatedly with physiological saline, dilute and be 10ml, pure water zeroing, 590nm place colorimetric survey absorbancy on spectrophotometer.(x ± s) expression relatively adopts the t check to testing data between group with mean ± standard deviation.The results are shown in Table 1.
The table 1 pair influence that the mouse peritoneal dyestuff oozes out (x ± s, n=10)
| Group | Dosage (mg/kg) | Absorbance |
| Dosage group high dose group positive controls in the control group low dose group | —— 38 75 150 15 | 2.608±1.254 2.242±1.344 1.068±0.723** 1.127±0.857** 1.382±0.984* |
(compare with control group, * shows P＜0.05, and * * shows P＜0.01, down together)
Table 1 shows that Radix Clematidis total glycosides can obviously reduce mouse peritoneal Evans Blue seepage discharge, compares with control group, and high, middle dosage group all has significant differences (p＜0.01), shows that Radix Clematidis total glycosides can suppress acetic acid and cause the increase of mouse vascular permeability.
2.2 dimethylbenzene inducing mouse ear swelling test
50 of mouse, grouping and the same 2.2.1 of administration, 1h smears dimethylbenzene 0.02ml in the two sides before and after mouse right ear after the last administration, left side ear compares, behind the 2h mouse dislocation is put to death, cut two ears, lay round auricle at same position respectively with the punch tool of diameter 8mm along the auricle baseline, weighing, is the swelling degree with the difference of left and right sides auricle weight.(x ± s) expression relatively adopts the t check to testing data between group with mean ± standard deviation.The results are shown in Table 2.
The influence of table 2 pair mice ear degree (x ± s, n=10)
| Group | Dosage (mg/kg) | Two ear weight differences (mg) |
| Dosage group high dose group positive controls in the control group low dose group | —— 38 75 150 15 | 0.982±0.333 0.613±0.290* 0.585±0.271** 0.525±0.432* 0.588±0.365* |
Table 2 shows that Radix Clematidis total glycosides can alleviate the mice ear degree, with control group relatively, low, all there were significant differences for high dose group (p＜0.05), middle dosage group has significant differences (p＜0.01), shows that Radix Clematidis total glycosides can suppress the chmice acute inflammation.
2.3 egg white is induced the rat paw edema test
30 of rats are divided into normal control group, Radix Clematidis total glycosides 25,50,100mg/kg group and positive controls (tripterygium glycosides sheet), 6 every group at random.Gastric infusion, once a day, for three days on end, the right toes subcutaneous injection of the every mouse of 1h 1% egg white 0.1ml causes inflammation after the last administration, respectively cause scorching before and cause scorching back 0.5h, measurement causes scorching parapodum volume, causing scorching forward and backward volumetrical difference with each mouse is the swelling degree.(x ± s) expression relatively adopts the t check to testing data between group with mean ± standard deviation.The results are shown in Table 3.
The influence of table 3 pair rat paw edema degree (x ± s, n=6)
| Group | Dosage (mg/kg) | Paw swelling (ml) |
| Dosage group high dose group positive controls in the control group low dose group | —— 25 50 100 10 | 0.46±0.11 0.32±0.13* 0.29±0.14* 0.26±0.11* 0.28±0.12* |
Table 3 shows that Radix Clematidis total glycosides can alleviate the rat paw edema degree, compares with control group, and all there were significant differences for high, medium and low dosage group (p＜0.05), shows that Radix Clematidis total glycosides can suppress the rat acute inflammation.
2.4 cotton balls inductive rat granuloma model
30 of rats are divided into 5 groups at random, and grouping is the same with administration, and the ether light anaesthesia is operated under aseptic condition, with cotton balls (each heavy 50mg ± 1mg, each cotton balls ammonification benzyl XiLin 1mg0.1mL behind the autoclaving
-1, 50 ℃ of oven dry) and to implant rat both sides inguinal region respectively subcutaneous, and operation began the ig administration same day, 7d continuously, the dislocation of d8 cervical vertebra causes death, and takes out cotton balls, puts that 60 ℃ of baking boxs are roasting to deduct the raw cotton ball weight to constant weight, is the granuloma net weight.Respectively organize granuloma weight.(x ± s) expression relatively adopts the t check to testing data between group with mean ± standard deviation.The results are shown in Table 4.
The influence of the swollen weight of table 4 pair rat granuloma (x ± s, n=6)
| Group | Dosage (mg/kg) | Granuloma weight (mg) |
| Dosage group high dose group positive controls in the control group low dose group | —— 25 50 100 10 | 42.25±5.77 38.78±2.09 33.55±3.33** 35.28±2.07* 33.87±2.46** |
Table 4 shows that Radix Clematidis total glycosides has significant inhibitory effect to cotton balls inductive rat granuloma, compare with control group, high dose group has significant difference (p＜0.05), and middle dosage group has significant differences (p＜0.01), shows that Radix Clematidis total glycosides can suppress the rat chronic inflammatory reaction.
2.5 mouse hot-plate analgesic test
50 of the qualified mouse in the preliminary election threshold of pain are divided into normal control group, Radix Clematidis total glycosides 38,75,150mgkg at random
-1Group and positive controls (tripterygium glycosides sheet), 10 every group.Gastric infusion is 3 days continuously, and the 1h mouse is measured by hot plate method and licks the sufficient time after the last administration.(x ± s) expression relatively adopts the t check to testing data between group with mean ± standard deviation.The results are shown in Table 5.
Table 5 pair mouse lick the foot time influence (x ± s, n=10)
| Group | Dosage (mg/kg) | Lick the sufficient time (s) |
| Dosage group high dose group positive controls in the control group low dose group | —— 38 75 150 15 | 20.82±4.49 30.36±17.61 30.99±9.43** 31.81±15.05* 26.70±6.18* |
Table 5 shows that Radix Clematidis total glycosides can obviously prolong mouse and lick the sufficient time, compares with control group, and high dose group has significant difference (p＜0.05), and middle dosage group has significant differences (p＜0.01), illustrates that Radix Clematidis total glycosides has obvious analgesic activity.
2.6 mouse writhing method analgesic test
50 of mouse, grouping and administration are with 2.5.The 0.5h mouse peritoneal is injected 0.6% acetum after the last administration, observes and write down mouse writhing reaction times in 15 minutes.(x ± s) expression relatively adopts the t check to testing data between group with mean ± standard deviation.The results are shown in Table 6.
The influence of table 6 pair mouse writhing number of times (x ± s, n=10)
| Group | Dosage (mg/kg) | Turn round the body number of times |
| Dosage group high dose group positive controls in the control group low dose group | —— 38 75 150 15 | 28±9 22±7 19±8* 17±5** 18±5** |
Table 6 shows that Radix Clematidis total glycosides can obviously reduce the mouse writhing number of times, compares with control group, and middle dosage group has significant difference (p＜0.05), and high dose group has significant differences (p＜0.01), illustrates that Radix Clematidis total glycosides has obvious analgesic activity.
2.7 influence to the autoimmune arthritis rat model
2.7.1 the model of rat assist agent arthritis model preparation
0.1ml causes inflammation in the left back toes intradermal injection of every mouse Freund's complete adjuvant.
2.7.2 medicine influences the primary pathology
48 of rats, be divided into blank group, model group, TSC group (high, medium and low dosage) medication group and positive controls (tripterygium glycosides) at random, every group 8, cause scorching preceding 3d ig administration, respectively at causing scorching forward and backward 3h, 6h and 24h, detection causes scorching forward and backward rat and causes scorching parapodum swelling, to observe AA rat primary pathology (seeing Table 7).
Table 7 TSC is to the influence of rat assist agent arthritis primary pathology (x ± s)
| Group | N (only) | Dosage (mg/kg) | Cause scorching back different time (h) sufficient sole of the foot volume (ml) | |||
| 0h | 3h | 6h | 24h | |||
| Dosage high dosage trypterygine group in the blank group model group low dosage | 8 8 8 8 8 8 | — — 25 50 100 10 | 1.68±0.20 1.73±0.20 1.65±0.18 1.64±0.26 1.73±0.25 1.70±0.34 | 1.68±0.20 2.29±0.21*** 1.86±0.25 △△ 2.03±0.23 △ 1.92±0.43 △ 2.01±0.23 △ | 1.68±0.20 2.46±0.22*** 1.90±0.33 △△ 2.15±0.27 △ 2.13±0.20 △△ 1.90±0.29 △△△ | 1.68±0.20 2.26±0.36** 1.88±0.28 △ 1.80±0.43 △ 1.90±0.24 △ 1.86±0.25 △ |
Annotate: the blank group of vs., * P＜0.05, * * P＜0.01, * * * P＜0.001;
Vs. model group,
△P＜0.05,
△ △P＜0.01,
△ △ △P＜0.001, down together
Table 7 is the result show: compare with model group, high, medium and low each the dosage group of TSC all has significant difference, shows that each dosage group of TSC all has significant difference to rat assist agent arthritis primary pathology.
2.7.3 medicine influences the Secondary cases pathology
Cause scorching back 4d and begin the ig administration, once a day, detected the non-scorching parapodum volume that causes respectively in the 7th, 11 day.Adopt joint scoring (0-4) simultaneously: (0 does not have redness, and 1 sufficient little toe redness and swelling of joints, 2 toe joint rednesses, the sufficient sole of the foot are all red and swollen, and 3 ankle joints are following all red and swollen, and 4 comprise ankle joint, whole red and swollen; Except that causing scorching side, the integration sum of tripodia is the joint total mark, is up to 12 fens), adopt Ridit value method that AA rat polyarthritis symptom is assessed, to observe AA rat Secondary cases pathology (seeing Table 2,3).
TSC is to the influence of rat assist agent arthritis Secondary cases pathology
The scoring of table 8 rat joint
| Group | Grade 0 | Grade 1 | Grade 2 | Grade 3 | VS. model group |
| Dosage in the model group low dosage | ?0 ?1 ?0 | ?1 ?9 ?5 | 12 8 13 | 14 6 3 | — P＜0.01 P＜0.05 |
| High dosage trypterygine group | 0 0 | 10 10 | 7 3 | 7 5 | P＜0.05 P＜0.01 |
Table 8 is the result show: TSC can effectively improve arthritic symptom.
Table 9 TSC is to the influence of rat assist agent arthritis Secondary cases pathology (x ± s)
| Group | n | Dosage (mg/kg) | Cause scorching metapedes sole of the foot volume (ml) | |
| 7d | 11d | |||
| Dosage high dosage trypterygine group in the blank group model group low dosage | 8 8 8 8 8 8 | — — 25 50 100 10 | 1.69±0.14 1.95±0.18** 1.85±0.21 1.76±0.18 1.72±0.19 △ 1.73±0.15 △ | 1.72±0.21 2.05±0.22** 1.90±0.14 1.78±0.21 △ 1.82±0.19 △ 1.77±0.18 △ |
Table 9 is the result show: compare with model group, the middle and high dosage group of TSC all has significant difference (p＜0.05) to rat assist agent arthritis Secondary cases pathology, shows that TSC has the significance effect to rat assist agent arthritis Secondary cases pathology.
Conclusion:
This experimental result shows that Radix Clematidis total glycosides of the present invention all has significant anti-inflammatory action to various inflammatory models, and adjuvant arthritis rats primary pathology and Secondary cases pathology are had in various degree preventive and therapeutic effect, also has remarkable analgesic activity simultaneously.Illustrate that Radix Clematidis total glycosides is used for the clinical treatment rheumatoid arthritis important therapeutic value is arranged.As seen, can be made into the medicine that rheumatoid arthritis is had therapeutic action with Radix Clematidis total glycosides.
Among the present invention, the extracting method of Radix Clematidis total glycosides is as follows:
With the Chinese medicine Root of Sixpetal Clematis is raw material, pulverizes the back with 70% alcohol reflux 2-3 time, united extraction liquid, and decompression recycling ethanol must concentrated extract.Medicinal extract dilutes with suitable quantity of water, last D
101Macroporous adsorptive resins absorption washes the solubility impurity that anhydrates earlier with water, again with 50% ethanol elution, collects 50% ethanol eluate, and concentrate drying must contain the Radix Clematidis total glycosides of multiple saponin constituent.
Claims (2)
1. one kind is the efficient part Radix Clematidis total glycosides that raw material extracts with the Chinese medicine Root of Sixpetal Clematis, it is characterized in that having following chemical structure:
R
1 R
2
Root of Sixpetal Clematis saponin(e CP
1OH 3-O-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
2H 3-O-α-L-rhamnosyl-(1-2)-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
2bH 3-O-β-D-wood sugar-(1-2)-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
3bOH 3-O-α-L-rhamnosyl-(1-2)-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
3H 3-O-β-D-wood sugar-(1-3)-α-L-rhamnosyl-(1-2)-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
4H 3-O-β-D-ribose-(1-3)-α-L-rhamnosyl-(1-2)-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
5OH 3-O-β-D-wood sugar-(1-3)-α-L-rhamnosyl-(1-2)-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
6OH 3-O-β-D-ribose-(1-3)-α-L-rhamnosyl-(1-2)-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
7H 3-O-β-D-glucose-(1-4)-β-D-ribose-(1-3)-α-L-rhamnosyl-(1-2)-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
8OH 3-O-β-D-glucose-(1-4)-β-D-ribose-(1-3)-α-L-rhamnosyl-(1-2)-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
9H 3-O-β-D-glucose-(1-4)-β-D-glucose-(1-4)-β-D-ribose-(1-3)-α-L-rhamnosyl-(1-2)
-α-L-arabinose
Root of Sixpetal Clematis saponin(e CP
10OH 3-O-β-D-glucose-(1-4)-β-D-glucose-(1-4)-β-D-ribose-(1-3)-α-L-rhamnosyl-(1-2)
-α-L-arabinose
2. Radix Clematidis total glycosides according to claim 1 is characterized in that making the medicine that rheumatoid arthritis is had therapeutic action with it.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510094339 CN1927878A (en) | 2005-09-09 | 2005-09-09 | Clematis chinensis total saponin and treatment action thereof for rheumatoild disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510094339 CN1927878A (en) | 2005-09-09 | 2005-09-09 | Clematis chinensis total saponin and treatment action thereof for rheumatoild disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1927878A true CN1927878A (en) | 2007-03-14 |
Family
ID=37858031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510094339 Pending CN1927878A (en) | 2005-09-09 | 2005-09-09 | Clematis chinensis total saponin and treatment action thereof for rheumatoild disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1927878A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058610A (en) * | 2011-01-10 | 2011-05-18 | 武汉道一堂医药研究院 | Application of triterpenoidsaponin compound to preparing antihypertensive drug |
| CN102068447A (en) * | 2011-01-10 | 2011-05-25 | 武汉道一堂医药研究院 | Application of triterpenoid saponin compound in preparation of medicaments for treating autoimmune diseases |
| EA025213B1 (en) * | 2015-01-22 | 2016-11-30 | Азербайджанский Медицинский Университет | Oleanolic acid pentaoside and method for producing the same from european ivy seeds |
| CN115477678A (en) * | 2022-08-31 | 2022-12-16 | 华南农业大学 | Preparation method of triterpene diglycoside compound and application of triterpene diglycoside compound in preparation of antitumor drugs |
| CN115671123A (en) * | 2021-07-21 | 2023-02-03 | 苏州凯祥生物科技有限公司 | Application of clematis root saponin in preparation of purine-lowering medicine |
| CN116173108A (en) * | 2023-02-28 | 2023-05-30 | 中国药科大学 | Application of total saponins of radix Clematidis in preparing medicine for treating rheumatoid arthritis complicated with pulmonary interstitial lesions |
-
2005
- 2005-09-09 CN CN 200510094339 patent/CN1927878A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058610A (en) * | 2011-01-10 | 2011-05-18 | 武汉道一堂医药研究院 | Application of triterpenoidsaponin compound to preparing antihypertensive drug |
| CN102068447A (en) * | 2011-01-10 | 2011-05-25 | 武汉道一堂医药研究院 | Application of triterpenoid saponin compound in preparation of medicaments for treating autoimmune diseases |
| CN102058610B (en) * | 2011-01-10 | 2012-12-12 | 武汉道一堂医药研究院 | Application of triterpenoidsaponin compound to preparing antihypertensive drug |
| CN102068447B (en) * | 2011-01-10 | 2013-03-06 | 武汉道一堂医药研究院 | Application of triterpenoid saponin compound in preparation of medicaments for treating autoimmune diseases |
| EA025213B1 (en) * | 2015-01-22 | 2016-11-30 | Азербайджанский Медицинский Университет | Oleanolic acid pentaoside and method for producing the same from european ivy seeds |
| CN115671123A (en) * | 2021-07-21 | 2023-02-03 | 苏州凯祥生物科技有限公司 | Application of clematis root saponin in preparation of purine-lowering medicine |
| CN115671123B (en) * | 2021-07-21 | 2024-03-22 | 苏州凯祥生物科技有限公司 | Application of clematis root saponin in preparation of purine-reducing medicament |
| CN115477678A (en) * | 2022-08-31 | 2022-12-16 | 华南农业大学 | Preparation method of triterpene diglycoside compound and application of triterpene diglycoside compound in preparation of antitumor drugs |
| CN116173108A (en) * | 2023-02-28 | 2023-05-30 | 中国药科大学 | Application of total saponins of radix Clematidis in preparing medicine for treating rheumatoid arthritis complicated with pulmonary interstitial lesions |
| CN116173108B (en) * | 2023-02-28 | 2024-03-19 | 中国药科大学 | Application of total saponins of radix Clematidis in preparing medicine for treating rheumatoid arthritis complicated with pulmonary interstitial lesions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101829075B (en) | Applications of kukoamine A and kukoamine B | |
| Peng et al. | Anti-allergic rhinitis effect of caffeoylxanthiazonoside isolated from fruits of Xanthium strumarium L. in rodent animals | |
| CN103800390B (en) | Health-care product with immunity-reinforcing and liver-protecting functions, preparation method and application thereof | |
| CN1927878A (en) | Clematis chinensis total saponin and treatment action thereof for rheumatoild disease | |
| CN1883618A (en) | Effective parts of cirald daphne bark, preparation method and application thereof | |
| CN104546992A (en) | Folium cortex eucommiae extract as well as preparation method and application thereof | |
| CN1680355A (en) | Preparation of suaveolic flavone for treating chronic pharyngitis and chronic tonsilltiis | |
| CN103735587A (en) | Kazakh traditional anti-inflammatory analgesic drug radix echinopsis extract and preparation method thereof | |
| CN1817898A (en) | Use of anti-inflammatory medicine for scheelite total saponin and its saponin compound | |
| CN102579559B (en) | Bauhinia championii ethyl acetate extract, n-butyl alcohol extract, and preparation methods and applications thereof | |
| CN100471865C (en) | Process for preparing notoginseng diol saponin | |
| Zhang et al. | Study on the effective material basis and mechanism of traditional Chinese medicine prescription (QJC) against stress diarrhea in mice | |
| CN102228666B (en) | Composition prepared from pine pollen and curcuma, preparation method thereof, and application of composition in preparing medicament for treating inflammatory bowel disease | |
| CN1973853A (en) | Hemostatic and analgetic medicine composition and its prepn process | |
| CN104491372A (en) | Radix scrophulariae buccal tablet | |
| CN101991811A (en) | Traditional Chinese medicine composition for treating rheumatism arthralgia, cold headache, abdominal cavity pain and chilblain and preparation method thereof | |
| CN103735575A (en) | Rhamnella gilgitica extract and preparation method and application thereof | |
| CN103110700A (en) | Fraxinus mandshurica extract for treating rheumatoid arthritis | |
| CN102139002A (en) | Cortex phellodendri polysaccharide extract and preparation method and medical application thereof | |
| CN101077364A (en) | Traditional Chinese medicine composition for treating cardio cerebrovasculer disease and its preparations and preparation method | |
| CN104095912A (en) | Traditional Chinese medicine formula for treating rheumatism bone disease and preparation method of Chinese patent medicine of traditional Chinese medicine formula | |
| CN102772548B (en) | A kind of preparation method for the treatment of the Chinese medicine composition of lupus erythematosus | |
| CN1270755C (en) | Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis | |
| CN1233383C (en) | Chinese medicinal preparation for treating prostate disease and its preparation method | |
| CN102940621A (en) | Application of methyl ferulic acid in preparation of medicine for preventing and curing hepatic fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |